CIN2
19
7
7
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
5.3%
1 terminated out of 19 trials
87.5%
+1.0% vs benchmark
32%
6 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (19)
Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya
Regression of Cervical Precancerous Lesions and Associated Risk Factors
Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV
Empowering Women - Shared Decision Making in Managing Cervical Precancer
Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.
Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Performance of Tampons as a Biospecimen Collection Tool for the Detection of Human Papillomavirus in a Colposcopy Setting
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Conservative Management of CIN2 Lesions and Biomarkers Evaluation
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
Cervical Cancer Screening With Human Papillomavirus Testing
Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Phase II Evaluation of AHCC for the Eradication of HPV Infections
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females